Improving drug benefits for children with asthma: results of a multi-stakeholder workshop to build a research agenda
Ungar WJ, Paterson M, Cope S, Kozyrskyj A. Healthc Policy. 2008; 3(4):66-77.
Publications
How complete are drug history profiles that are based on public drug benefit claims?
Paterson JM, Suleiman A, Hux JE, Bell C. Can J Clin Pharmacol. 2008; 15(1):e108-16. Epub 2008 Feb 19.
Effect of cost-sharing on use of asthma medication in children
Ungar W, Kozyrskyj A, Paterson M, Ahmad F. Arch Pediatr Adolesc Med. 2008; 162(2):104-10.
The Ontario Wait Time Strategy: No Evidence of an Adverse Impact on Other Surgeries
Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario
Mamdani M, Warren L, Kopp A, Paterson JM, Laupacis A, Bassett K, Anderson GM. CMAJ. 2006; 175(12):1535-8.
Clinical consequences of generic warfarin substitution: an ecological study
Paterson JM, Mamdani M, Juurlink DN, Naglie G, Laupacis A, Stukel TA. JAMA. 2006; 296(16):1969-72.
Case selection for statins was similar in two Canadian provinces: BC and Ontario
Paterson JM, Carney G, Anderson GM, Bassett K, Naglie G, Laupacis A; BC-Ontario Pharmacosurveillance for Decision-making Collaborative. J Clin Epidemiol. 2007; 60(1):73-8. Epub 2006 Sep 7.
Using pharmacoepidemiology to inform drug coverage policy: initial lessons from a two-province collaborative
Paterson JM, Laupacis A, Bassett K, Anderson GM; BC-Ontario Pharmacosurveillance for Decision-Making Collaborative. Health Aff. 2006; 25(5):1436-43.
Concordance between discharge prescriptions and insurance claims in post-myocardial infarction patients
Jackevicius CA, Paterson JM, Naglie G. Pharmacoepidemiol Drug Saf. 2007; 16(2):207-15.
Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach
Laupacis A, Paterson JM, Mamdani M, Rostom A, Anderson GM. CMAJ. 2003; 169(11):1167-70.